ADMA Biologics (NASDAQ: ADMA) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare ADMA Biologics to related businesses based on the strength of its valuation, analyst recommendations, dividends, earnings, profitability, risk and institutional ownership.

Insider and Institutional Ownership

32.8% of ADMA Biologics shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 60.4% of ADMA Biologics shares are owned by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

ADMA Biologics has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500. Comparatively, ADMA Biologics’ rivals have a beta of 2.55, suggesting that their average share price is 155% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for ADMA Biologics and its rivals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ADMA Biologics 0 0 2 0 3.00
ADMA Biologics Competitors 815 3185 11552 230 2.71

ADMA Biologics currently has a consensus target price of $9.00, suggesting a potential upside of 202.01%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.58%. Given ADMA Biologics’ stronger consensus rating and higher possible upside, analysts clearly believe ADMA Biologics is more favorable than its rivals.

Earnings & Valuation

This table compares ADMA Biologics and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
ADMA Biologics $10.66 million -$19.51 million -1.49
ADMA Biologics Competitors $284.30 million $34.29 million 126.98

ADMA Biologics’ rivals have higher revenue and earnings than ADMA Biologics. ADMA Biologics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.


This table compares ADMA Biologics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ADMA Biologics -35.00% -76.26% -9.77%
ADMA Biologics Competitors -5,335.75% -434.35% -39.86%


ADMA Biologics beats its rivals on 7 of the 12 factors compared.

About ADMA Biologics

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.

Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with's FREE daily email newsletter.